Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

A Prospective Cohort Study of Efficacy, Safety and Characterization of Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

Hematopoietic stem cell transplantation (HSCT) is a cellular therapy aiming at curing some hematological diseases. Upon transplantation, recipients experience a phase of profound immune suppression with loss of protective immunity against most infectious agents. Revaccination of HSCT recipients against vaccine-preventable infections is an important post-transplant intervention for reducing morbi-mortality. The VaccHemInf project aims at assessing the efficacy of recommended vaccines in adult recipients of HSCT, through the antibody titers reference method and a panel of immune functional assays.

Inclusion Criteria:

• allogeneic and autologous HSCT recipients

• ≥ 18 year-old

• patients having been informed of the conditions of the study (24-month follow-up) and having signed the informed consent form

• Person with social security insurance

  • Additional inclusion criteria for healthy volunteers enrolled (10 volunteers)in the ancillary study of influenza vaccine response:

• health-care workers recruited from the hospital staff

Exclusion Criteria:

• Patient with innate or acquired immune deficiency (severe combined immunodeficiency, Hepatitis C virus (HCV), HBV, HIV infections at any stage)
• Pregnant or breastfeeding women
• History of previous severe allergic reaction to vaccine components
• Patient with no social security coverage, with restricted liberty or under legal protection.